<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03489564</url>
  </required_header>
  <id_info>
    <org_study_id>PBRC 2017-065</org_study_id>
    <nct_id>NCT03489564</nct_id>
  </id_info>
  <brief_title>Mitochondrial Capacity in Pregnant Women</brief_title>
  <acronym>Mito Moms</acronym>
  <official_title>The Effect of Physical Activity on in Vivo and in Vitro Mitochondrial Capacity in Pregnant Women</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pennington Biomedical Research Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pennington Biomedical Research Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This Pilot &amp; Feasibility study will test the hypothesis that pregnant women who are more&#xD;
      active will have better functioning mitochondria in vivo (higher ATPmax, via 31P-MRS), which&#xD;
      will be positively related to maternal and infant mitochondrial function in vitro (higher&#xD;
      oxygen consumption rates in primary myotubes and umbilical cord derived mesenchymal stem&#xD;
      cells, respectively). Twenty pregnant women (10 active and 10 sedentary) will be recruited in&#xD;
      the first trimester of pregnancy determined from self-reported physical activity and&#xD;
      assessment by activity monitors. Placental biospecimens will be collected during delivery for&#xD;
      other molecular mitochondrial analyses.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 19, 2018</start_date>
  <completion_date type="Actual">February 11, 2020</completion_date>
  <primary_completion_date type="Actual">February 11, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Infant in vitro mitochondrial capacity (by oxygen consumption rate)</measure>
    <time_frame>1 day</time_frame>
    <description>Infant in vitro mitochondrial capacity measured by oxygen consumption rates in umbilical cord derived mesenchymal stem cells at delivery</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Relationship between in vivo mitochondrial capacity and infant in vitro mitochondrial capacity (by oxygen consumption rates)</measure>
    <time_frame>About 20 weeks</time_frame>
    <description>Relationship between in vivo and in vitro mitochondrial capacity will be measured with in vivo mitochondrial capacity measured by 31P-MRS and infant in vitro mitochondrial capacity measured by oxygen consumption rates in umbilical cord derived mesenchymal stem cells</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relationship between in vivo mitochondrial capacity and maternal in vitro mitochondrial capacity (by oxygen consumption rate)</measure>
    <time_frame>About 15 weeks</time_frame>
    <description>Relationship between in vivo and in vitro mitochondrial capacity will be measured with in vivo mitochondrial capacity measured by 31P-MRS and maternal in vitro mitochondrial capacity measured by oxygen consumption rates in maternal primary myotubes</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">20</enrollment>
  <condition>Pregnancy Related</condition>
  <condition>Physical Activity</condition>
  <arm_group>
    <arm_group_label>Active</arm_group_label>
    <description>Physically active will be defined by self-report and confirmed by step counts &gt;8,000 per day from activity monitoring.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sedentary</arm_group_label>
    <description>Sedentary lifestyle will be defined by self-report and confirmed by step counts &lt;5,000 per day from activity monitoring.</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Active</intervention_name>
    <description>No behavioral intervention included but the exposure is level of physical activity. Individuals in the Active group will be categorized by their own routine physical activity levels.</description>
    <arm_group_label>Active</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Sedentary</intervention_name>
    <description>No behavioral intervention included but the exposure is level of physical activity. Individuals in the Sedentary group will be categorized by their own routine physical activity levels.</description>
    <arm_group_label>Sedentary</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Placental biospecimens (placenta, umbilical cord, cord blood). Leg muscle tissue.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Healthy women that are classified as either physically active or sedentary in early&#xD;
        pregnancy.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Pregnant female&#xD;
&#xD;
          -  BMI between 18.5 kg/m2 and 30.0 kg/m2 prior to the current pregnancy (determined by&#xD;
             self report and confirmation of pregravid BMI of the index pregnancy from the prenatal&#xD;
             record)&#xD;
&#xD;
          -  Medically cleared for participation in the study by primary care obstetrician or&#xD;
             midwife&#xD;
&#xD;
          -  Medically cleared for participation by the Medical Investigator&#xD;
&#xD;
          -  Medical record release (prenatal record, hospital delivery record) for study staff to&#xD;
             access information in the medical record related to the current and if applicable, the&#xD;
             prior pregnancy.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Risk of early delivery (eg. history of preterm birth, spontaneous abortion, evidence&#xD;
             of gestational hypertension (SBP &gt;160 mmHg &amp; DBP &gt;110 mmHg) or pre-eclampsia in the&#xD;
             current pregnancy)&#xD;
&#xD;
          -  History of intrauterine growth-restriction&#xD;
&#xD;
          -  Persistent second- or third-trimester bleeding&#xD;
&#xD;
          -  Placenta previa after 26 weeks gestation&#xD;
&#xD;
          -  Incompetent cervix or cerclage&#xD;
&#xD;
          -  Severe anemia&#xD;
&#xD;
          -  High-order pregnancy (e.g. triplets)&#xD;
&#xD;
          -  Family history of diabetes&#xD;
&#xD;
          -  Heart or lung disease&#xD;
&#xD;
          -  HIV or AIDS (self-reported)&#xD;
&#xD;
          -  Individuals with contraindication to magnetic resonance spectroscopy such as having&#xD;
             magnetic metallic objects in their body&#xD;
&#xD;
          -  Unwillingness for placental biospecimens to be collected at delivery&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Female</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Leanne M Redman, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Pennington Biomedical Research Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pennington Biomedical Research Center</name>
      <address>
        <city>Baton Rouge</city>
        <state>Louisiana</state>
        <zip>70808</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.pbrc.edu/clinical-trials/?studyid=260</url>
    <description>Pennington Biomedical Research Center website description and webscreener survey</description>
  </link>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>March 29, 2018</study_first_submitted>
  <study_first_submitted_qc>March 29, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">April 5, 2018</study_first_posted>
  <last_update_submitted>August 23, 2021</last_update_submitted>
  <last_update_submitted_qc>August 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Pennington Biomedical Research Center</investigator_affiliation>
    <investigator_full_name>Leanne Redman</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>Pregnancy</keyword>
  <keyword>Mitochondrial metabolism</keyword>
  <keyword>Placenta</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

